IMPLICATIONS OF ICD-10 FOR SARCOPENIA CLINICAL PRACTICE AND CLINICAL TRIALS: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE
IMPLICATIONS OF ICD-10 FOR SARCOPENIA CLINICAL PRACTICE AND CLINICAL TRIALS: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE
复制标题
DOI：
10.14283/jfa.2017.30
复制
发表时间：
2018-01-01
影响因子：
3.9
通讯作者：
Cesari, M.
中科院分区：
文献类型：
--
作者：
Vellas, B.;Fielding, R. A.;Cesari, M.
2016年建立的ICD-10-CM骨骼肌减少症代码是朝着就需要建立与年龄相关的骨骼肌衰退的分类学框架达成国际共识迈出的重要一步。2017年4月，虚弱和骨骼肌减少症研究工作组召开了国际会议，讨论了实施新准则的意义、意义和障碍，以及加速新疗法开发的策略。肌少症定义和结果联盟正在进行分析，以制定肌少症的定量定义。计划召开一次协商一致的会议来评价这一分析。工作组还讨论了从骨骼肌减少症试验中获得的可应用于未来试验的经验教训，以及骨质疏松症领域的经验教训，骨质疏松症是一种与骨骼肌减少症有许多相似结构的临床疾病，监管机构已经开发并批准了针对这种疾病的特殊治疗方法。
Establishment of an ICD-10-CM code for sarcopenia in 2016 was an important step towards reaching international consensus on the need for a nosological framework of age-related skeletal muscle decline. The International Conference on Frailty and Sarcopenia Research Task Force met in April 2017 to discuss the meaning, significance, and barriers to the implementation of the new code as well as strategies to accelerate development of new therapies. Analyses by the Sarcopenia Definitions and Outcomes Consortium are underway to develop quantitative definitions of sarcopenia. A consensus conference is planned to evaluate this analysis. The Task Force also discussed lessons learned from sarcopenia trials that could be applied to future trials, as well as lessons from the osteoporosis field, a clinical condition with many constructs similar to sarcopenia and for which ad hoc treatments have been developed and approved by regulatory agencies.